Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 6/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6446003 | 1.00 | SLC1A2 (0.56) | SLC1A2SLC1A1PKMCYP1A2ALDH1A1 | |
| SCHEMBL10756908 | 0.73 | PKM (0.61) | SLC1A2SLC1A1PKMCYP1A2ALDH1A1 | |
| SCHEMBL15184252 | 0.73 | PKM (0.61) | SLC1A2SLC1A1PKMCYP1A2ALDH1A1 | |
| SCHEMBL2412292 | 0.73 | PKM (0.61) | SLC1A2SLC1A1PKMCYP1A2ALDH1A1 | |
| SCHEMBL15613797 | 0.73 | PKM (0.61) | SLC1A2SLC1A1PKMCYP1A2ALDH1A1 | |
| SCHEMBL501299 | 0.73 | PKM (0.61) | SLC1A2SLC1A1PKMCYP1A2ALDH1A1 | |
| SCHEMBL2365101 | 0.73 | PKM (0.61) | SLC1A2SLC1A1PKMCYP1A2ALDH1A1 | |
| SCHEMBL15676663 | 0.73 | PKM (0.61) | SLC1A2SLC1A1PKMCYP1A2ALDH1A1 | |
| SCHEMBL13447407 | 0.73 | PKM (0.61) | SLC1A2SLC1A1PKMCYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL500436 | 0.72 | PKM (0.59) | SLC1A2SLC1A1PKMCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615886-A1 | [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | Warner-Lambert Company LLC (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092134-A1 | [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | claimed |
| EP-1680125-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | Warner-Lambert Company LLC (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1615886-A1 | [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | Warner-Lambert Company LLC (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005002585-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| WO-2004092134-A1 | [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | SLC1A2 1631/4885SLC1A1 1989/4885PKM 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.